Cancer Research

Pharma company releases data from phase 1 for nonHodgkin's B-cell lymphomas

Published in Cancer Weekly, October 19th, 2004

Pharmacyclics, Inc., (NASDAQ:PCYC) announced that interim study results with Xcytrin (motexafin gadolinium) Injection in combination with Rituxan and Zevalin for the treatment of relapsed and refractory nonHodgkin's B-cell lymphomas were presented at the 6th International Symposium on Hodgkin Lymphoma in Cologne, Germany.

The presentation, made by Dr. Andrew Evens of the hematology/oncology department at Northwestern University's Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center in Chicago, Illinois, also included laboratory studies providing evidence that Xcytrin localizes in lymphoma cells, generates reactive oxygen species, and induces...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-10-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry